{"id":22906,"date":"2025-03-11T19:49:05","date_gmt":"2025-03-11T18:49:05","guid":{"rendered":"https:\/\/santediabete.org\/?p=22906"},"modified":"2025-03-11T22:40:31","modified_gmt":"2025-03-11T21:40:31","slug":"linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi","status":"publish","type":"post","link":"https:\/\/santediabete.org\/en_en\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/","title":{"rendered":"Biosimilar Insulin Significantly Lowers HbA1c in Mali, But Access Remains a Challenge"},"content":{"rendered":"<p><img data-recalc-dims=\"1\" decoding=\"async\" class=\"size-medium wp-image-22907 aligncenter\" src=\"https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307-600x472.jpg?resize=600%2C472&#038;ssl=1\" alt=\"Un professionnel de sant\u00e9 montre un stylo \u00e0 insuline biosimilaire \u00e0 un jeune patient\" width=\"600\" height=\"472\" srcset=\"https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?resize=600%2C472&amp;ssl=1 600w, https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?resize=1024%2C805&amp;ssl=1 1024w, https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?resize=768%2C604&amp;ssl=1 768w, https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?resize=1536%2C1208&amp;ssl=1 1536w, https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?resize=15%2C12&amp;ssl=1 15w, https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?w=2035&amp;ssl=1 2035w\" sizes=\"(max-width: 600px) 100vw, 600px\" \/><\/p>\n<p style=\"text-align: center;\">\u00a0\u00a9 Sant\u00e9 Diab\u00e8te<\/p>\n<p><em>A glossary of the key scientific terms used in this press release is available at the end.<\/em><\/p>\n<p><strong>Bamako, Mali \u2013 March 12, 2025<\/strong> \u2013 Our new study published in <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.70007\"><em>Diabetic Medicine<\/em><\/a> has demonstrated significant improvements in glycaemic control among children and young adults living with Type 1 Diabetes (T1D) in Mali following the introduction of biosimilar glargine, a long-acting analogue insulin. This randomised controlled trial assessed the impact of usual care using long-acting and short-acting human insulin delivered using syringes versus switching the long-acting human insulin for biosimilar glargine administered via reusable pens.<\/p>\n<p>The trial, which involved 260 participants under 25 years of age, found a marked reduction in HbA1c levels in the intervention group. Over 12 months, mean HbA1c levels in this group dropped from 103 mmol\/mol (11.6%) to 65 mmol\/mol (8.1%) (<em>p<\/em> &lt; 0.001), whereas the control group, which continued on human insulin therapy, only saw a minor improvement from 101 mmol\/mol (11.4%) to 93 mmol\/mol (10.7%) (<em>p<\/em> &lt; 0.01). Notably, the proportion of participants with high HbA1c (\u2265130 mmol\/mol or 14%) fell to 0% in the intervention group, compared to a modest decline in the control group.<\/p>\n<h3><strong>Key Strengths of the Study:<\/strong><\/h3>\n<ul>\n<li><strong>Robust Study Design:<\/strong> The trial employed a rigorous randomised controlled approach, ensuring reliable comparisons between intervention and control groups.<\/li>\n<li><strong>Large Sample Size:<\/strong> The inclusion of 260 participants strengthened the statistical power of the study and its applicability to similar settings.<\/li>\n<li><strong>Comprehensive Diabetes Education:<\/strong> Both study groups received extensive diabetes self-management training, ensuring that any improvements were directly attributable to the change in insulin therapy rather than differences in patient education.<\/li>\n<li><strong>High Adherence to Study Protocol:<\/strong> Apart from two premature deaths unrelated to the study protocol, all participants completed the trial, resulting in a comprehensive dataset.<\/li>\n<\/ul>\n<p>Beyond the clinical results the study underscores the feasibility of transitioning to a basal-bolus insulin regimen with biosimilar insulin glargine in resource-limited settings.<\/p>\n<p>For <strong>St\u00e9phane Besan\u00e7on<\/strong>, director of <strong>Sant\u00e9 Diab\u00e8te<\/strong> and co-lead author of the study:<br \/>\n<em>\u201cThe results of this study are highly compelling from a clinical point of view, but the issue of access to insulin, be it human or analogue remains unresolved in many low-and-middle-income countries like Mali. In these contexts, the issue of affordability for individuals and health systems remains a key barrier to ensuring proper outcomes for people with type 1 diabetes.\u201d<\/em><\/p>\n<blockquote><p>The study underscores the feasibility of transitioning to a basal-bolus insulin regimen with biosimilar insulin glargine in resource-limited settings.<\/p><\/blockquote>\n<p>Work done by the <strong>ACCISS study<\/strong> (<em>(Addressing the Challenge and Constraints of Insulin Sources and Supply)<\/em>, led by <strong>Health Action International<\/strong> and the<strong>the University of Geneva<\/strong>, in partnership with <strong>Sant\u00e9 Diab\u00e8te<\/strong>, has found that the median price individuals need to pay for analogue insulin in the public sector is <strong>7 times higher<\/strong> than human insulin.<\/p>\n<p><strong>David Beran<\/strong>, Assistant Professor at the<strong>the University of Geneva<\/strong> and also a co-author of the study, adds:<br \/>\n<em>\u201cThis study is an excellent example of a collaboration and enabled new data to be generated as this is the first study of its kind in a context like Mali. However, in translating this science to policy and practice we cannot negate the wider health system factors that come with introducing a new medicine, especially one that is more expensive. Given these results we now need to work on guaranteeing access to insulin at affordable prices.\u201d<\/em><\/p>\n<blockquote><p>The median price individuals need to pay for analogue insulin in the public sector is 7 times higher than human insulin.<\/p><\/blockquote>\n<h3><strong>Next Steps: Urgent Actions for Equitable Access to Insulin<\/strong><\/h3>\n<p>Ensuring sustainable and affordable access to both human and analogue insulin is a critical next step in improving diabetes care worldwide. <a href=\"https:\/\/www.who.int\/news-room\/feature-stories\/detail\/first-ever-global-coverage-targets-for-diabetes-adopted-at-the-75-th-world-health-assembly\">The World Health Organization's global targets coverage include<\/a> that\u00a0<em>\"100% of people with type 1 diabetes have access to affordable insulin and blood glucose self-monitoring\"<\/em>. In order to achieve this, urgent action is required, including:<\/p>\n<ol>\n<li><strong>The World Health Organization (WHO):<\/strong><\/li>\n<\/ol>\n<ol>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>Promote the uptake of Prequalification of insulin<\/li>\n<li>Develop practical guidance for countries to improve access to insulin and strengthen health systems for the management of type 1 diabetes.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<ol start=\"2\">\n<li><strong>The pharmaceutical industry:<\/strong><\/li>\n<\/ol>\n<ol>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>To implement their stated differential pricing commitments.<\/li>\n<li>To work with partners to reduce their prices of analogue insulin significantly to  guarantee equitable access for patients.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<ol start=\"3\">\n<li><strong>Governments:<\/strong><\/li>\n<\/ol>\n<ol>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>To integrate insulin and diabetes care into Universal Health Coverage (UHC) packages, ensuring that life-saving treatment is accessible to all who need it.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<ol start=\"4\">\n<li><strong>Civil society:<\/strong><\/li>\n<\/ol>\n<ol>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>To advocate and ensure the voices of people living with diabetes are heard<\/li>\n<li>To document and disseminate evidence<\/li>\n<li>To hold the private sector and governments to account<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<h3><\/h3>\n<h3><strong>For more information, please contact:<\/strong><\/h3>\n<p><strong>St\u00e9phane Besan\u00e7on<\/strong><br \/>\nDirector of the NGO Sant\u00e9 Diab\u00e8te<br \/>\n<a href=\"mailto:stephane.besancon@santediabete.org\">stephane.besancon@santediabete.org<\/a><\/p>\n<h3><strong>About the study:<\/strong><\/h3>\n<p>The study was funded by the <strong>Leona M. and Harry B. Helmsley Charitable Trust<\/strong> and was conducted by the specialists in endocrinology in Mali with the NGO <strong>Sant\u00e9 Diab\u00e8te<\/strong>, in collaboration with the <strong>Life for a Child program<\/strong>,<strong>the University of Geneva<\/strong>, the <strong>Geneva University Hospitals<\/strong>,<strong>the University of Luxembourg<\/strong> and the<strong>University of Sidney<\/strong>.<\/p>\n<h3><strong>Glossary of Key Scientific Terms:<\/strong><\/h3>\n<ul>\n<li><strong>Type 1 diabetes (T1D)<\/strong> \u2013 A chronic autoimmune condition in which the pancreas does not produce insulin.<\/li>\n<li><strong>Glycaemic Control<\/strong> \u2013 The management of blood sugar (glucose) levels within a target range to prevent complications.<\/li>\n<li><strong>HbA1c (Glycated Hemoglobin)<\/strong> \u2013 A measure of average blood sugar levels over the past 2\u20133 months, expressed in mmol\/mol (%) to assess long-term diabetes control.<\/li>\n<li><strong>Biosimilar insulin<\/strong> \u2013 A biologic insulin product that is highly similar to an already approved reference insulin, with no clinically meaningful differences in efficacy or safety.<\/li>\n<li><strong>Glargine (Insulin Glargine)<\/strong> \u2013 A long-acting analogue insulin used to maintain stable blood sugar levels throughout the day and night.<\/li>\n<li><strong>Basal-Bolus Insulin Regimen<\/strong> \u2013 A diabetes treatment strategy combining long-acting (basal) insulin and short-acting (bolus) insulin to mimic natural insulin secretion.<\/li>\n<li><strong>Randomised Controlled Trial (RCT)<\/strong> \u2013 A study design that randomly assigns participants to an intervention group or a control group to compare outcomes scientifically.<\/li>\n<li><strong>Intervention Group<\/strong> \u2013 The group of participants in a clinical study receiving the experimental treatment (e.g., biosimilar insulin glargine in this trial).<\/li>\n<li><strong>Control Group<\/strong> \u2013 The group of participants receiving standard care or placebo, used as a comparison for measuring the effects of the intervention.<\/li>\n<li><strong>Statistical Significance (<\/strong><em><strong>p-value)<\/strong><\/em><strong>)<\/strong> \u2013 A measure indicating whether the results of a study are likely due to chance. A <em>p-value)<\/em> p-value of &lt;0.05 suggests strong evidence against chance findings.<\/li>\n<li><strong>Universal Health Coverage (UHC)<\/strong> \u2013 A healthcare system ensuring that all individuals receive the medical services they need without financial hardship.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u00a0\u00a9 Sant\u00e9 Diab\u00e8te Un glossaire des principaux termes scientifiques mentionn\u00e9s dans ce communiqu\u00e9 est disponible \u00e0 la fin. Bamako, Mali \u2013 12 mars 2025 \u2013 Notre nouvelle \u00e9tude publi\u00e9e dans Diabetic Medicine d\u00e9montre une am\u00e9lioration significative du contr\u00f4le glyc\u00e9mique chez les enfants et jeunes adultes atteints de diab\u00e8te de type 1 (DT1) au Mali apr\u00e8s&hellip;<\/p>","protected":false},"author":15,"featured_media":22907,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[15],"tags":[],"class_list":["post-22906","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communique-de-presse"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>L&#039;insuline biosimilaire r\u00e9duit significativement l&#039;HbA1c au Mali, mais l&#039;acc\u00e8s reste un d\u00e9fi &#8211; Sant\u00e9 Diab\u00e8te<\/title>\n<meta name=\"description\" content=\"Notre \u00e9tude au Mali montre l&#039;impact de la glargine biosimilaire sur le contr\u00f4le glyc\u00e9mique des jeunes atteints de diab\u00e8te de type 1. D\u00e9couvrez les r\u00e9sultats cl\u00e9s, les d\u00e9fis d&#039;acc\u00e8s \u00e0 l&#039;insuline dans les pays \u00e0 ressources limit\u00e9\u00e9es, et les actions urgentes pour garantir un acc\u00e8s \u00e9quitable \u00e0 l&#039;insuline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/santediabete.org\/en_en\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L&#039;insuline biosimilaire r\u00e9duit significativement l&#039;HbA1c au Mali, mais l&#039;acc\u00e8s reste un d\u00e9fi &#8211; Sant\u00e9 Diab\u00e8te\" \/>\n<meta property=\"og:description\" content=\"Notre \u00e9tude au Mali montre l&#039;impact de la glargine biosimilaire sur le contr\u00f4le glyc\u00e9mique des jeunes atteints de diab\u00e8te de type 1. D\u00e9couvrez les r\u00e9sultats cl\u00e9s, les d\u00e9fis d&#039;acc\u00e8s \u00e0 l&#039;insuline dans les pays \u00e0 ressources limit\u00e9\u00e9es, et les actions urgentes pour garantir un acc\u00e8s \u00e9quitable \u00e0 l&#039;insuline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/santediabete.org\/en_en\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/\" \/>\n<meta property=\"og:site_name\" content=\"Sant\u00e9 Diab\u00e8te\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ONGSantDiabte\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-11T18:49:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-11T21:40:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2035\" \/>\n\t<meta property=\"og:image:height\" content=\"1600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nina Tousch\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ongsantdiabte\" \/>\n<meta name=\"twitter:site\" content=\"@ongsantdiabte\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nina Tousch\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/\"},\"author\":{\"name\":\"Nina Tousch\",\"@id\":\"https:\/\/santediabete.org\/#\/schema\/person\/05b828b3280ae06db55166e4862867f0\"},\"headline\":\"L&rsquo;insuline biosimilaire r\u00e9duit significativement l&rsquo;HbA1c au Mali, mais l&rsquo;acc\u00e8s reste un d\u00e9fi\",\"datePublished\":\"2025-03-11T18:49:05+00:00\",\"dateModified\":\"2025-03-11T21:40:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/\"},\"wordCount\":1326,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/santediabete.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?fit=2035%2C1600&ssl=1\",\"articleSection\":[\"Communiqu\u00e9 de presse\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/\",\"url\":\"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/\",\"name\":\"L'insuline biosimilaire r\u00e9duit significativement l'HbA1c au Mali, mais l'acc\u00e8s reste un d\u00e9fi &#8211; Sant\u00e9 Diab\u00e8te\",\"isPartOf\":{\"@id\":\"https:\/\/santediabete.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?fit=2035%2C1600&ssl=1\",\"datePublished\":\"2025-03-11T18:49:05+00:00\",\"dateModified\":\"2025-03-11T21:40:31+00:00\",\"description\":\"Notre \u00e9tude au Mali montre l'impact de la glargine biosimilaire sur le contr\u00f4le glyc\u00e9mique des jeunes atteints de diab\u00e8te de type 1. D\u00e9couvrez les r\u00e9sultats cl\u00e9s, les d\u00e9fis d'acc\u00e8s \u00e0 l'insuline dans les pays \u00e0 ressources limit\u00e9\u00e9es, et les actions urgentes pour garantir un acc\u00e8s \u00e9quitable \u00e0 l'insuline.\",\"breadcrumb\":{\"@id\":\"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#primaryimage\",\"url\":\"https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?fit=2035%2C1600&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?fit=2035%2C1600&ssl=1\",\"width\":2035,\"height\":1600,\"caption\":\"Un professionnel de sant\u00e9 montre un stylo \u00e0 insuline biosimilaire \u00e0 un jeune patient\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/santediabete.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L&rsquo;insuline biosimilaire r\u00e9duit significativement l&rsquo;HbA1c au Mali, mais l&rsquo;acc\u00e8s reste un d\u00e9fi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/santediabete.org\/#website\",\"url\":\"https:\/\/santediabete.org\/\",\"name\":\"ONG Sante Diab\u00e8te\",\"description\":\"Innover ensemble pour lutter contre le diab\u00e8te en Afrique\",\"publisher\":{\"@id\":\"https:\/\/santediabete.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/santediabete.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/santediabete.org\/#organization\",\"name\":\"ONG Sant\u00e9 Diab\u00e8te\",\"url\":\"https:\/\/santediabete.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/santediabete.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/santediabete.org\/wp-content\/uploads\/2019\/05\/santediabete-logo.png\",\"contentUrl\":\"https:\/\/santediabete.org\/wp-content\/uploads\/2019\/05\/santediabete-logo.png\",\"width\":311,\"height\":66,\"caption\":\"ONG Sant\u00e9 Diab\u00e8te\"},\"image\":{\"@id\":\"https:\/\/santediabete.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ONGSantDiabte\/\",\"https:\/\/x.com\/ongsantdiabte\",\"https:\/\/www.instagram.com\/santediabeteofficiel\/\",\"https:\/\/www.linkedin.com\/company\/ngo-sant\u00e9-diab\u00e8te\/\",\"https:\/\/www.youtube.com\/channel\/UCTjyy-p0F6FSXjJ54nLXdVA\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/santediabete.org\/#\/schema\/person\/05b828b3280ae06db55166e4862867f0\",\"name\":\"Nina Tousch\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/santediabete.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ce9162cdc248c39f2498dea5ed6646ff4851b12910bab170497f927b52573a0e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ce9162cdc248c39f2498dea5ed6646ff4851b12910bab170497f927b52573a0e?s=96&d=mm&r=g\",\"caption\":\"Nina Tousch\"},\"url\":\"https:\/\/santediabete.org\/en_en\/author\/nina-tousch\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L'insuline biosimilaire r\u00e9duit significativement l'HbA1c au Mali, mais l'acc\u00e8s reste un d\u00e9fi &#8211; Sant\u00e9 Diab\u00e8te","description":"Notre \u00e9tude au Mali montre l'impact de la glargine biosimilaire sur le contr\u00f4le glyc\u00e9mique des jeunes atteints de diab\u00e8te de type 1. D\u00e9couvrez les r\u00e9sultats cl\u00e9s, les d\u00e9fis d'acc\u00e8s \u00e0 l'insuline dans les pays \u00e0 ressources limit\u00e9\u00e9es, et les actions urgentes pour garantir un acc\u00e8s \u00e9quitable \u00e0 l'insuline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/santediabete.org\/en_en\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/","og_locale":"en_GB","og_type":"article","og_title":"L'insuline biosimilaire r\u00e9duit significativement l'HbA1c au Mali, mais l'acc\u00e8s reste un d\u00e9fi &#8211; Sant\u00e9 Diab\u00e8te","og_description":"Notre \u00e9tude au Mali montre l'impact de la glargine biosimilaire sur le contr\u00f4le glyc\u00e9mique des jeunes atteints de diab\u00e8te de type 1. D\u00e9couvrez les r\u00e9sultats cl\u00e9s, les d\u00e9fis d'acc\u00e8s \u00e0 l'insuline dans les pays \u00e0 ressources limit\u00e9\u00e9es, et les actions urgentes pour garantir un acc\u00e8s \u00e9quitable \u00e0 l'insuline.","og_url":"https:\/\/santediabete.org\/en_en\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/","og_site_name":"Sant\u00e9 Diab\u00e8te","article_publisher":"https:\/\/www.facebook.com\/ONGSantDiabte\/","article_published_time":"2025-03-11T18:49:05+00:00","article_modified_time":"2025-03-11T21:40:31+00:00","og_image":[{"width":2035,"height":1600,"url":"https:\/\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg","type":"image\/jpeg"}],"author":"Nina Tousch","twitter_card":"summary_large_image","twitter_creator":"@ongsantdiabte","twitter_site":"@ongsantdiabte","twitter_misc":{"Written by":"Nina Tousch","Estimated reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#article","isPartOf":{"@id":"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/"},"author":{"name":"Nina Tousch","@id":"https:\/\/santediabete.org\/#\/schema\/person\/05b828b3280ae06db55166e4862867f0"},"headline":"L&rsquo;insuline biosimilaire r\u00e9duit significativement l&rsquo;HbA1c au Mali, mais l&rsquo;acc\u00e8s reste un d\u00e9fi","datePublished":"2025-03-11T18:49:05+00:00","dateModified":"2025-03-11T21:40:31+00:00","mainEntityOfPage":{"@id":"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/"},"wordCount":1326,"commentCount":0,"publisher":{"@id":"https:\/\/santediabete.org\/#organization"},"image":{"@id":"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?fit=2035%2C1600&ssl=1","articleSection":["Communiqu\u00e9 de presse"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/","url":"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/","name":"L'insuline biosimilaire r\u00e9duit significativement l'HbA1c au Mali, mais l'acc\u00e8s reste un d\u00e9fi &#8211; Sant\u00e9 Diab\u00e8te","isPartOf":{"@id":"https:\/\/santediabete.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#primaryimage"},"image":{"@id":"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?fit=2035%2C1600&ssl=1","datePublished":"2025-03-11T18:49:05+00:00","dateModified":"2025-03-11T21:40:31+00:00","description":"Notre \u00e9tude au Mali montre l'impact de la glargine biosimilaire sur le contr\u00f4le glyc\u00e9mique des jeunes atteints de diab\u00e8te de type 1. D\u00e9couvrez les r\u00e9sultats cl\u00e9s, les d\u00e9fis d'acc\u00e8s \u00e0 l'insuline dans les pays \u00e0 ressources limit\u00e9\u00e9es, et les actions urgentes pour garantir un acc\u00e8s \u00e9quitable \u00e0 l'insuline.","breadcrumb":{"@id":"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#primaryimage","url":"https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?fit=2035%2C1600&ssl=1","contentUrl":"https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?fit=2035%2C1600&ssl=1","width":2035,"height":1600,"caption":"Un professionnel de sant\u00e9 montre un stylo \u00e0 insuline biosimilaire \u00e0 un jeune patient"},{"@type":"BreadcrumbList","@id":"https:\/\/santediabete.org\/2025\/03\/11\/linsuline-biosimilaire-reduit-significativement-lhba1c-au-mali-mais-lacces-reste-un-defi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/santediabete.org\/"},{"@type":"ListItem","position":2,"name":"L&rsquo;insuline biosimilaire r\u00e9duit significativement l&rsquo;HbA1c au Mali, mais l&rsquo;acc\u00e8s reste un d\u00e9fi"}]},{"@type":"WebSite","@id":"https:\/\/santediabete.org\/#website","url":"https:\/\/santediabete.org\/","name":"ONG Sante Diab\u00e8te","description":"Innover ensemble pour lutter contre le diab\u00e8te en Afrique","publisher":{"@id":"https:\/\/santediabete.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/santediabete.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/santediabete.org\/#organization","name":"NGO Sant\u00e9 Diab\u00e8te","url":"https:\/\/santediabete.org\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/santediabete.org\/#\/schema\/logo\/image\/","url":"https:\/\/santediabete.org\/wp-content\/uploads\/2019\/05\/santediabete-logo.png","contentUrl":"https:\/\/santediabete.org\/wp-content\/uploads\/2019\/05\/santediabete-logo.png","width":311,"height":66,"caption":"ONG Sant\u00e9 Diab\u00e8te"},"image":{"@id":"https:\/\/santediabete.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ONGSantDiabte\/","https:\/\/x.com\/ongsantdiabte","https:\/\/www.instagram.com\/santediabeteofficiel\/","https:\/\/www.linkedin.com\/company\/ngo-sant\u00e9-diab\u00e8te\/","https:\/\/www.youtube.com\/channel\/UCTjyy-p0F6FSXjJ54nLXdVA"]},{"@type":"Person","@id":"https:\/\/santediabete.org\/#\/schema\/person\/05b828b3280ae06db55166e4862867f0","name":"Nina Tousch","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/santediabete.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ce9162cdc248c39f2498dea5ed6646ff4851b12910bab170497f927b52573a0e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ce9162cdc248c39f2498dea5ed6646ff4851b12910bab170497f927b52573a0e?s=96&d=mm&r=g","caption":"Nina Tousch"},"url":"https:\/\/santediabete.org\/en_en\/author\/nina-tousch\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/santediabete.org\/wp-content\/uploads\/2025\/03\/MG_0159-scaled-e1741718574307.jpg?fit=2035%2C1600&ssl=1","jetpack-related-posts":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/santediabete.org\/en_en\/wp-json\/wp\/v2\/posts\/22906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/santediabete.org\/en_en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/santediabete.org\/en_en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/santediabete.org\/en_en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/santediabete.org\/en_en\/wp-json\/wp\/v2\/comments?post=22906"}],"version-history":[{"count":3,"href":"https:\/\/santediabete.org\/en_en\/wp-json\/wp\/v2\/posts\/22906\/revisions"}],"predecessor-version":[{"id":22910,"href":"https:\/\/santediabete.org\/en_en\/wp-json\/wp\/v2\/posts\/22906\/revisions\/22910"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/santediabete.org\/en_en\/wp-json\/wp\/v2\/media\/22907"}],"wp:attachment":[{"href":"https:\/\/santediabete.org\/en_en\/wp-json\/wp\/v2\/media?parent=22906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/santediabete.org\/en_en\/wp-json\/wp\/v2\/categories?post=22906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/santediabete.org\/en_en\/wp-json\/wp\/v2\/tags?post=22906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}